JP6517833B2 - 神経変性疾患の処置に有用なウィザノライド - Google Patents

神経変性疾患の処置に有用なウィザノライド Download PDF

Info

Publication number
JP6517833B2
JP6517833B2 JP2016554830A JP2016554830A JP6517833B2 JP 6517833 B2 JP6517833 B2 JP 6517833B2 JP 2016554830 A JP2016554830 A JP 2016554830A JP 2016554830 A JP2016554830 A JP 2016554830A JP 6517833 B2 JP6517833 B2 JP 6517833B2
Authority
JP
Japan
Prior art keywords
patient
acid
methyl
hydrogen
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016554830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537432A (ja
JP2016537432A5 (enExample
Inventor
アンソニー エー． ショー，
アンソニー エー． ショー，
ジャン−ピエール ジュリエン，
ジャン−ピエール ジュリエン，
アグネス エイチ． チャン，
アグネス エイチ． チャン，
Original Assignee
イムスター セラピューティクス インコーポレイテッド
イムスター セラピューティクス インコーポレイテッド
ユニバルシテ ラバル
ユニバルシテ ラバル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムスター セラピューティクス インコーポレイテッド, イムスター セラピューティクス インコーポレイテッド, ユニバルシテ ラバル, ユニバルシテ ラバル filed Critical イムスター セラピューティクス インコーポレイテッド
Publication of JP2016537432A publication Critical patent/JP2016537432A/ja
Publication of JP2016537432A5 publication Critical patent/JP2016537432A5/ja
Application granted granted Critical
Publication of JP6517833B2 publication Critical patent/JP6517833B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2016554830A 2013-11-25 2014-11-25 神経変性疾患の処置に有用なウィザノライド Expired - Fee Related JP6517833B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908455P 2013-11-25 2013-11-25
US61/908,455 2013-11-25
PCT/US2014/067436 WO2015077780A1 (en) 2013-11-25 2014-11-25 Withanolides useful for the treatment of neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2016537432A JP2016537432A (ja) 2016-12-01
JP2016537432A5 JP2016537432A5 (enExample) 2018-01-11
JP6517833B2 true JP6517833B2 (ja) 2019-05-22

Family

ID=52023694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016554830A Expired - Fee Related JP6517833B2 (ja) 2013-11-25 2014-11-25 神経変性疾患の処置に有用なウィザノライド

Country Status (14)

Country Link
US (1) US10351590B2 (enExample)
EP (1) EP3074414B1 (enExample)
JP (1) JP6517833B2 (enExample)
KR (1) KR20160137945A (enExample)
CN (1) CN105940010B (enExample)
AU (1) AU2014352629B2 (enExample)
BR (1) BR112016012002A2 (enExample)
CA (1) CA2931064C (enExample)
ES (1) ES2728870T3 (enExample)
MX (1) MX364528B (enExample)
PL (1) PL3074414T3 (enExample)
TR (1) TR201905218T4 (enExample)
WO (1) WO2015077780A1 (enExample)
ZA (1) ZA201603117B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019116069A1 (en) * 2017-12-11 2019-06-20 Ethnodyne Compounds for treating neurodegenerative disorders
US20210087222A1 (en) * 2017-12-11 2021-03-25 Ethnodyne Compounds for treating neurodegenerative disorders
EP3724207A1 (en) * 2017-12-11 2020-10-21 Ethnodyne Compounds for treating neurodegenerative disorders
CN111377994A (zh) * 2018-12-28 2020-07-07 南开大学 七种来源于灯笼果的醉茄内酯类化合物及其制备方法和用途
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
CN116063373B (zh) * 2023-02-14 2025-04-15 广西医科大学 天然产物27-Deoxywithaferin A的制备方法
EP4788688A1 (en) * 2023-10-03 2026-08-12 Enveda Therapeutics, Inc. Withaferin a analog and method for treatment using the same
CN117924401B (zh) * 2024-01-22 2026-05-12 黑龙江中医药大学 一种具有神经炎症抑制活性的化合物及其提取方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010030395A2 (en) * 2008-09-15 2010-03-18 Whitehead Institute For Biomedical Research Withaferin a analogs and uses thereof
WO2010053655A2 (en) 2008-11-07 2010-05-14 University Of Kansas Therapeutic methods with withaferin a and analogs
US8598339B2 (en) 2011-02-01 2013-12-03 University Of Kansas Withanolide isolated from Physalis longifolia and analogs and methods of use thereof
ES2679289T3 (es) * 2011-06-22 2018-08-23 UNIVERSITé LAVAL Procedimientos para el pronóstico y/o diagnóstico de una enfermedad neurodegenerativa, procedimientos para identificar compuestos candidatos y compuestos para tratar una enfermedad neurodegenerativa

Also Published As

Publication number Publication date
KR20160137945A (ko) 2016-12-02
EP3074414A1 (en) 2016-10-05
WO2015077780A1 (en) 2015-05-28
MX364528B (es) 2019-04-30
AU2014352629B2 (en) 2019-03-28
JP2016537432A (ja) 2016-12-01
MX2016006544A (es) 2016-12-12
CN105940010B (zh) 2018-03-30
PL3074414T3 (pl) 2019-12-31
US10351590B2 (en) 2019-07-16
CN105940010A (zh) 2016-09-14
CA2931064A1 (en) 2015-05-28
CA2931064C (en) 2022-10-18
EP3074414B1 (en) 2019-01-09
BR112016012002A2 (pt) 2017-09-19
US20170022247A1 (en) 2017-01-26
ES2728870T3 (es) 2019-10-29
ZA201603117B (en) 2020-05-27
AU2014352629A1 (en) 2016-05-26
TR201905218T4 (tr) 2019-05-21

Similar Documents

Publication Publication Date Title
CA2931064C (en) Withanolides useful for the treatment of neurodegenerative diseases
CN106103452B (zh) 皮质抑素类似物及其合成和用途
TW202237087A (zh) 作為醫藥活性化合物之大麻素衍生物及其製備方法
EA035016B1 (ru) Проникающее в мозг производное оксима хромона для терапии леводопа-индуцированной дискинезии
CN112047944A (zh) 一种选择性抑制激酶化合物及其用途
US11472832B2 (en) Withanolides useful for the treatment of neurodegenerative diseases
RU2672569C2 (ru) Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата
JP7295145B2 (ja) 神経変性疾患を治療するための医薬及びその使用
WO2022125613A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
CN107820495A (zh) 靶向epha4的配体结合域的新型epha4抑制剂
US20190127320A1 (en) Kcnq2-5 channel activator
EP4587418A1 (en) Compounds for the treatment of neuromuscular disorders
CN118510544A (zh) 大麻素类的磷酸酯前药
JP7185226B2 (ja) １，５－アンヒドロフルクトース誘導体を含むａｍｐｋ活性化剤
WO2022125614A1 (en) Phosphonates as inhibitors of enpp1 and cdnp
JP7382944B2 (ja) 神経変性疾患を予防・治療するための新規な化合物及びその応用
WO2026101751A1 (en) Positron emission tomography radiotracers for the complement c3a receptor
JP2026509274A (ja) ソルチリン活性の修飾剤
CN117903092A (zh) 二羟基苯酞类化合物及其制备方法和用途
JP2026067759A (ja) Ｃ３ａ受容体拮抗化合物及びその利用
JP2024507798A (ja) 抗コリンエステラーゼ活性を有する６－メチルウラシル誘導体およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190418

R150 Certificate of patent or registration of utility model

Ref document number: 6517833

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees